WOCKPHARMA Stock Overview
A pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Wockhardt Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,482.05 |
| 52 Week High | ₹1,536.60 |
| 52 Week Low | ₹376.45 |
| Beta | 1.57 |
| 1 Month Change | 26.65% |
| 3 Month Change | 54.73% |
| 1 Year Change | 256.82% |
| 3 Year Change | 278.99% |
| 5 Year Change | 506.16% |
| Change since IPO | 449.28% |
Recent News & Updates
What Wockhardt Limited's (NSE:WOCKPHARMA) 31% Share Price Gain Is Not Telling You
Dec 17
Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up
Nov 02Recent updates
What Wockhardt Limited's (NSE:WOCKPHARMA) 31% Share Price Gain Is Not Telling You
Dec 17Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up
Nov 02What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You
Aug 20Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jul 27Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Jun 30Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation
Jun 22Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%
Feb 21There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump
Dec 19There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues
Oct 14Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?
Jun 23Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Feb 18Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jan 04Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being
Jul 26Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
May 18Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Jan 26
What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?
Dec 01Shareholder Returns
| WOCKPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.9% | -0.4% | 0.2% |
| 1Y | 256.8% | 40.7% | 23.9% |
Return vs Industry: WOCKPHARMA exceeded the Indian Pharmaceuticals industry which returned 40.7% over the past year.
Return vs Market: WOCKPHARMA exceeded the Indian Market which returned 23.9% over the past year.
Price Volatility
| WOCKPHARMA volatility | |
|---|---|
| WOCKPHARMA Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: WOCKPHARMA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: WOCKPHARMA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 2,386 | Murtaza Khorakiwala | www.wockhardt.com |
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. The company develops qualified infectious diseases products comprising WCK5222, which is in phase 3 clinical trial for the treatment of sepsis and hospital/ventilator associated pneumonia; WCK 4282, which is in phase 3 clinical trial for ESBL infections; WCK 6777, which is phase 1 to treat gram negative infections; and WCK 4873, which is phase 3 clinical trial for community-acquired bacterial pneumonia. It also offers rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices.
Wockhardt Limited Fundamentals Summary
| WOCKPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹240.79b |
| Earnings (TTM) | -₹2.88b |
| Revenue (TTM) | ₹29.81b |
8.1x
P/S Ratio-83.6x
P/E RatioIs WOCKPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WOCKPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹29.81b |
| Cost of Revenue | ₹12.73b |
| Gross Profit | ₹17.08b |
| Other Expenses | ₹19.96b |
| Earnings | -₹2.88b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -17.73 |
| Gross Margin | 57.30% |
| Net Profit Margin | -9.66% |
| Debt/Equity Ratio | 58.0% |
How did WOCKPHARMA perform over the long term?
See historical performance and comparison